Spyre Therapeutics
SYRE
77 hedge funds and large institutions have $322M invested in Spyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 10 closing their positions.
97% more capital inflows, than outflows
Capital inflows: $29M | Capital outflows: $14.7M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
1.09% less ownership
Funds ownership: 83.78% → 82.69% (-1.1%)
1% less funds holding
Funds holding: 78 → 77 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Laurion Capital Management
New York
|
+$4.24M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.15M |
| 3 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$1.03M |
| 4 |
Suvretta Capital Management
New York
|
+$445K |
| 5 |
Renaissance Technologies
New York
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boxer Capital
San Diego,
California
|
-$3.83M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.27M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.35M |
| 4 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.12M |
| 5 |
BlackRock
New York
|
-$839K |
SYRE Hedge Fund Activity: Q3 2021 in Review
77 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2021, worth a combined $322M — up 13% from $286M a quarter earlier.
Fund positioning in SYRE was balanced in Q3 2021: 10 funds opened new positions, 10 closed out, 23 added to existing stakes and 23 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $4.24M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.83M sold.
- 77 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2021, down from 78 in Q2 2021.
- Funds reported $322M of Spyre Therapeutics stock for Q3 2021, up 13% quarter-over-quarter.
- 10 funds opened new Spyre Therapeutics positions in Q3 2021 and 10 closed out, a net change of 0 holders.
- The largest Spyre Therapeutics buyer in Q3 2021 was Laurion Capital Management, an estimated $4.24M added.
- The largest Spyre Therapeutics seller in Q3 2021 was Boxer Capital, an estimated $3.83M sold.
Based on aggregated 13F filings for Q3 2021.